<DOC>
	<DOC>NCT01598311</DOC>
	<brief_summary>608 patients with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study and receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.</brief_summary>
	<brief_title>A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>To be included in this study, participants must: Sign a consent form; Be older 18 or older and 90 or younger; Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device; Test positive for Clostridium difficile; If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study. Participants will not be allowed into the study if they: Have toxic megacolon and/or known small bowel ileus; Have received treatment with intravenous immune globulin (IVIG)within the past 30 days; Have received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study; Have received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working; Have received an investigational vaccine against C. difficile; Have received an investigational product containing monoclonal antibodies against toxin A or B within 180 days; Had more than 2 episodes of CDAD within 90 days; Had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months(this does not include appendectomy or cholecystectomy); Have history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis; Are unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study; Are unable to discontinue opiate treatment unless on a stable dose; Has known positive stool cultures for other enteropathogens including but not limited to Salmonella, Shigella, and Campylobacter; Had stool studies positive for pathogenic ova and/or parasites; Have an intolerance or hypersensitivity to daptomycin and/or vancomycin; Have lifethreatening illness at the time of enrollment; Have poor concurrent medical risks that in the opinion of the Investigator the participant should not enroll; Have received an investigational drug or participated in any experimental procedure within 1 month; Have HIV, a CD4 &lt;200 cells/mm3 within 6 months of start of study therapy; Anticipate that certain antibacterial therapy for a nonCDAD infection will be required for &gt;7 days; Are unable to discontinue Saccharomyces or similar probiotic; Are on a concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy; Are unable to comply with the protocol requirements; Have any condition that, in the opinion of the Investigator, might interfere; Are not expected to live for less than 8 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>CDAD</keyword>
	<keyword>Clostridium difficile Associated Diarrhea</keyword>
	<keyword>CDI</keyword>
	<keyword>Clostridium difficile Infection</keyword>
	<keyword>Diarrhea</keyword>
</DOC>